LBLidewij Sophia Boogers

Lidewij Sophia Boogers

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Lidewij Sophia Boogers has a total of 62 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Response to Letter to the Editor on “Feminine figures: body image and physical characteristics in trans women after puberty suppression and subsequent estradiol therapy”

    by Lidewij S Boogers, Elena S F McDonnell, Annelou L C de Vries, Martin Den Heijer, A S Paul van Trotsenburg, Chantal M Wiepjes, Sabine E Hannema

  • Open Access

    Feminine figures: body image and physical characteristics in trans women after puberty suppression and subsequent estradiol therapy

    by Lidewij S Boogers, Elena S F McDonnell, Annelou L C de Vries, Martin Den Heijer, A S Paul van Trotsenburg, Sabine E Hannema, Chantal M Wiepjes

    Background: Several studies have demonstrated an improvement in body image following gender–affirming hormone treatment (GAHT). In transgender girls, puberty suppression (PS) can be initiated before GAHT to prevent masculinization. Aim: The aim of this study is to assess body image, self-esteem and its determinants in trans women who received PS prior to GAHT. Methods: Forty-two trans women from a specialized gender clinic who initiated treatment <18 years were included in this cross-sectional study of whom 23 initiated PS in early puberty (Tanner stage G2-3), and 19 in late puberty (Tanner stage G4-5). Outcomes: Body Image Scale (BIS) scores, ranging from 1 (very satisfied) to 5 (very dissatisfied), Rosenberg self-esteem scores and anthropometric measurements were collected. Results: Participants were aged 20.1 ± 2.0 years and used GAHT for 4.2 ± 1.6 years. Mean total BIS score was 2.4 ± 0.6, indicating satisfaction. Height, BMI, foot length, and waist circumference correlated with corresponding BIS items, with smaller measurements being associated with higher satisfaction. Although total BIS scores were comparable between the early and late pubertal group (β0.3, 95% CI –0.05;0.7), most BIS items (24/27) scored lower in the early PS group, particularly voice (β-1.4, 95% CI –1.9;–0.8), Adam’s apple (β-0.6 95% CI –1.2;0.001) and weight (β-1.1 95% CI –1.9;–0.4). Self-esteem correlated negatively with BIS scores (β-4.5, 95% CI –6.6;–2.5). Clinical implications: This study reports the potential benefits of PS, especially when initiated early in puberty, on body satisfaction, particularly with voice, and self-esteem in trans women. Clinicians should consider these outcomes when counseling on gender-affirming care and its timing, while also addressing many other factors potentially affecting body image and self-esteem, such as mental wellbeing, social support, quality of life, and other physical parameters like obesity. Strengths and limitations: Strengths include systematic data collection and the integration of objective and subjective variables. Limitations include a small sample size and potential selection bias due to exclusion criteria and non-participation, possibly affecting generalizability. Conclusion: Trans women using PS prior to GAHT are overall satisfied with their bodies and have average self-esteem. More feminine anthropometric measurements correspond to higher body satisfaction. Moreover, early start with PS is associated with higher satisfaction with voice, a characteristic strongly influenced by pubertal testosterone exposure.


  • Open Access

    The attitudes of transgender and gender-diverse adolescents and their parents regarding fertility, parenthood, and fertility preservation before the start of puberty suppression or gender-affirming hormone therapy

    by Tessa H R Stolk, Norah M van Mello, Lidewij S Boogers, Andreas Meißner, Judith A F Huirne, Alessandra D Fisher, Silvia Ciancia, Daniel Klink, Martine Cools, Sabine E Hannema, et al.

    Background: Gender-affirming treatment for transgender and gender-diverse (TGD) adolescents can consist of puberty suppression (PS) and gender-affirming hormone treatment (GAHT), which may affect fertility. Aim: This study aims to evaluate the attitudes and decision-making regarding parenthood and fertility preservation from TGD adolescents and their parents and analyze the fertility preservation use and outcome before the start of treatment. Methods: Adolescents under 18 starting PS or GAHT between November 2021 and March 2024 were enrolled in a multicenter prospective cohort study “ENIGI adolescents,” conducted at Amsterdam University Medical Centre, Ghent University Hospital, and Florence University Hospital. Adolescents and parents were asked to complete the “Transgender Youth Fertility Attitudes Questionnaire” and the “Decision Conflict Scale.” Information about fertility preservation use and outcomes was extracted from electronic patient files. Outcomes: Attitudes from TGD adolescents and their parents regarding desire for children, fertility preservation use, outcomes, and decision-making. Results: A total of 316 adolescents were counseled about fertility options; 100 (49%) registered female at birth (RFAB) and 50 (48%) registered male at birth (RMAB) adolescents expressed a future desire for children. More than 1/3 had interest in or are still undecided about having a genetic offspring. None of the RFAB TGD adolescents underwent fertility preservation. In total, 20 (22%) RMAB adolescents pursued fertility preservation, 14 before PS and 6 before GAHT. Before PS, three performed testicular sperm extraction (TESE). All others performed semen cryopreservation. The post-thawed semen quality was low. The testicular volume and Tanner stage in the semen cryopreservation group were significantly higher compared to TESE, P = .013 and P = .021, respectively. There was no significant difference in age between those groups. Adolescents experience moderate to high decisional conflict about their fertility choices. RFAB adolescents experience a significantly higher conflict in decision-making compared to RMAB adolescents (40/100 vs 34/100 95% CI [2.1-9.4]). Younger RFAB adolescents experienced more decisional conflict (B =−1,25, 95% CI [−2,25, −0.25]). In RMAB this was not significant. Clinical Implications: This study helps to further understand TGD adolescents’ needs and can further improve the development of tailored fertility counseling. Strengths and Limitations: This is the first European collaborative study on transgender healthcare in adolescents. A limitation of our study is the relatively low response rate to the questionnaires, which varied between 25% and 62%. Conclusion: Many TGD adolescents express a desire for future parenthood yet experience decisional conflict about their reproductive options, even after receiving comprehensive fertility counseling prior to PS or GAHT.


  • Open Access

    Gonadal function and pathology in 17beta-HSD 3 and 5alpha-reductase deficiency

    by Lidewij S Boogers, Hennie T Brüggenwirth, Katja P Wolffenbuttel, Remko Hersmus, Jillian Bryce, S Faisal Ahmed, Angela K Lucas-Herald, Federico Baronio, Martine Cools, Mona Ellaithi, et al.

    Objective: 17β-Hydroxysteroid dehydrogenase 3 deficiency (17β-HSDD) and 5α-reductase type 2 deficiency (5α-RD) are rare 46,XY differences of sex development (DSD). This study aims to enlarge the limited knowledge on long-term gonadal function and gonadal pathology in these conditions. Design: Retrospective multicentre cohort study. Methods: Data on phenotype, laboratory results, and hormone treatment were collected from patients aged ≥16 years at time of data collection with genetically confirmed 17β-HSDD and 5α-RD from 10 centres via the I-DSD Registry. If gonadectomy or gonadal biopsy had been performed, pathology reports and/or gonadal tissue or images were collected. Results: All 16 patients with 17β-HSDD were raised female; 1 (6%) changed to male gender at age 14. Three females were treated with gonadotrophin-releasing hormone agonists (GnRHa) to prevent virilisation. Thirteen underwent gonadectomy at median age 8 (range 0-17). None had germ cell (pre)malignancies. Of 14 patients with 5α-RD, 10 (71%) were raised female. Five changed gender at age 7-23, of whom 4 to male gender. One was treated with GnRHa. Six underwent gonadectomy at median age 10 (range 0-31). None had germ cell (pre)malignancies. With gonads in situ, puberty spontaneously progressed. Three were treated with dihydrotestosterone. Conclusions: A significant percentage of individuals with 17β-HSDD and 5α-RD changed gender, and some were treated with GnRHa to prevent virilisation before making a definitive decision about gonadectomy. When left in situ, spontaneous puberty occurs and germ cell (pre)malignancies seem uncommon at least until early adulthood. Together, these data support delaying a decision about gonadectomy until late adolescence in these conditions.


  • Open Access

    The natural course of bone mineral density in transgender youth before medical treatment; a cross sectional study

    by Maria Anna Theodora Catharina van der Loos, Lidewij Sophia Boogers, Daniel Tatting Klink, Martin Den Heijer, Chantal Maria Wiepjes, Sabine Elisabeth Hannema

    Objective: Bone mineral density (BMD) Z-scores decrease during puberty suppression in transgender youth. Assessment of treatment impact has been based on the assumption that without intervention, BMD Z-scores remain stable. However, the natural course of BMD in this population is unknown. Design: Retrospective cross-sectional study. Methods: Dual-energy X-ray absorptiometry scans prior to medical intervention were included from 333 individuals assigned male at birth (AMAB) and 556 individuals assigned female at birth (AFAB) aged 12–25 years. The relationship between age and BMD Z-scores of sex assigned at birth was analysed for the lumbar spine (LS), total hip (TH), femoral neck (FN), and total-body-less-head (TBLH), adjusted for height SDS, height-adjusted lean mass Z-score, and whole body percentage fat Z-score. Results: In individuals AMAB, the BMD Z-score was negatively associated with age between 12 and 22 years: LS −0.13/year (95% confidence interval, CI −0.17; −0.10); TH −0.05/year (95% CI −0.08; −0.02); FN −0.06/year (95% CI −0.10; −0.03); and TBLH −0.12/year (95% CI −0.15; −0.09). Adjusting for height-adjusted lean mass Z-score attenuated the association at the LS and TBLH and eliminated the association at the TH and FN. BMD Z-scores and age were not associated between 22 and 25 years. In individuals AFAB, BMD Z-scores were only associated with age at the TBLH (−0.08/year, 95% CI −0.12; −0.04) between age 12 and 20 years. Conclusion: In individuals AMAB aged 12–22 years prior to any treatment, BMD Z-scores were inversely correlated with age. This could imply that BMD increases less in individuals AMAB than in the general population, and that changes in Z-score during puberty suppression and subsequent hormone supplementation are not necessarily due to treatment, but possibly related to lifestyle factors.


  • Open Access

    Variations in Volume: Breast Size in Trans Women in Relation to Timing of Testosterone Suppression

    by Lidewij S Boogers, Sebastiaan A Sardo Infirri, Asma Bouchareb, Benthe A M Dijkman, Danithsia Helder, Christel J M de Blok, Niels P T J Liberton, Martin Den Heijer, A S Paul van Trotsenburg, Koen M A Dreijerink, et al.

    Context: Breast development is an important outcome for trans women receiving gender-affirming hormone therapy (GAHT). Limited breast development has been reported, possibly because of testosterone exposure during puberty. The impact of puberty suppression (PS) on breast development is unclear. Objective: To investigate the impact of PS and timing of PS prior to GAHT on breast volume and satisfaction. Methods: In a cross-sectional study at a tertiary gender identity clinic, 60 trans women (aged 17-57 years) after 4.5 ± 1.7 years of GAHT were included, of whom 23 initiated PS early in puberty (Tanner stage G2-3), 17 late in puberty (Tanner stage G4-5), and 20 started GAHT in adulthood without prior PS. Breast volume was measured with a 3D scanner and breast satisfaction measured with a questionnaire. Comparisons of breast volumes were adjusted for fat percentage. Results: Median breast volume was 115 mL (IQR, 68; 203), ie, bra cup size < A. Breast volume was 47 mL (95% CI, −9; 104) larger in the late PS group compared to early PS but this difference was only 4 mL (95% CI, −67; 75) after correction for fat percentage. Breast volume in the adult group was comparable to the early and late PS groups (adult vs early PS 27 mL [95% CI, −28; 83] and adult vs late PS −20 mL [95% CI, −80; 40]). In total, 68% of subjects were satisfied with breast size (57% of early PS, 76% of late PS, and 70% of adult group). Conclusion: Early start of PS was not associated with larger breast volume, suggesting that pubertal testosterone exposure does not affect breast volume after subsequent GAHT. Despite limited breast size, most trans women were satisfied with their breast development.


  • Open Access

    Shaping the Skeleton: Impact of GnRH Analogue and Sex Hormone Therapy on Skeletal Dimensions in Transgender Individuals

    by Lidewij Sophia Boogers, Boukje Teatske Sikma, Mark-Bram Bouman, Adrianus Sarinus Paulus van Trotsenburg, Martin Den Heijer, Chantal Maria Wiepjes, Sabine Elisabeth Hannema

    Context Skeletal dimensions vary between sexes. Men typically have broader shoulders and women a wider pelvis. If gender affirming hormone therapy (GAHT) with or without prior puberty suppression (PS) alters these dimensions in transgender individuals remains unclear. Objective To investigate impact of PS and GAHT on skeletal dimensions. Design Retrospective cross-sectional study. Setting Gender identity clinic. Participants Transgender individuals assigned male at birth (AMAB) and assigned female at birth (AFAB) who underwent dual-energy X-ray absorptiometry (DXA) scanning between ages 18 and 28 years were divided into four groups: Early PS (Tanner G/B2-3)+GAHT, Late PS (Tanner G/B4-5)+GAHT, GAHT only, and Untreated. Main outcome measures Shoulder and pelvis dimensions measured by DXA scan were compared between groups, with adjustment for height. Results A total of 121 individuals AMAB and 122 AFAB were included. Only in individuals AMAB who underwent early PS had smaller shoulders compared to untreated individuals AMAB (-1.3 cm; 95%CI -2.1; -0.5). In individuals AMAB from both the early and late PS group, pelvic inlet, pubic symphysis width and interischial distance were greater compared to untreated individuals AMAB resulting in dimensions comparable to untreated individuals AFAB. Only in early PS AFAB pelvic inlet width was smaller compared to untreated individuals AFAB (-1.0 cm; 95%CI -1.5; -0.6), and comparable to untreated individuals AMAB. Conclusions The study results suggest that skeletal dimensions are only altered by GAHT if endogenous puberty has not yet been completed at start of PS. These findings enhance our understanding of hormonal effects on the skeleton and may hold clinical relevance for body image as well as for forensic anthropology. Future research should evaluate clinical implications for surgical or obstetrical outcomes in transgender individuals.


  • Open Access

    A European Network for the Investigation of Gender Incongruence in adolescents

    by Lidewij S Boogers, Chantal M Wiepjes, Annemieke S Staphorsius, Daniel T Klink, Silvia Ciancia, Alessia Romani, Tessa H R Stolk, Emmy van Den Boogaard, Thomas D Steensma, Annelou L C de Vries, et al.

    Background: Knowledge regarding the effects and side effects of gender-affirming hormone therapy (GAHT) in adults is rapidly growing, partly through international research networks such as the European Network for the Investigation of Gender Incongruence (ENIGI). However, data on the effects of puberty suppression (PS) and GAHT in transgender and gender diverse (TGD) youth are limited, although these data are of crucial importance, given the controversies surrounding this treatment. Aim: We sought to present a detailed overview of the design of the ENIGI Adolescents study protocol, including the first baseline data. Methods: The ENIGI Adolescents study is an ongoing multicenter prospective cohort study. This study protocol was developed by 3 European centers that provide endocrine care for TGD adolescents and were already part of the ENIGI collaboration: Amsterdam, Ghent, and Florence. Outcomes: Study outcomes include physical effects and side effects, laboratory parameters, bone mineral density, anthropometric characteristics, attitudes toward fertility and fertility preservation, and psychological well-being, which are measured in the study participants during PS and GAHT, up to 3 years after the start of GAHT. Results: Between November 2021 and May 2023, 172 TGD adolescents were included in the ENIGI Adolescents protocol, of whom 51 were assigned male at birth (AMAB) and 121 were assigned female at birth (AFAB); 3 AFAB participants reported a nonbinary gender identification. A total of 76 participants were included at the start of PS, at a median (IQR) age of 13.7 (12.9-16.5) years in AMAB and 13.5 (12.4-16.1) years in AFAB individuals. The remaining 96 participants were included at start of GAHT, at a median (IQR) age of 15.9 (15.1-17.4) years in AFAB and 16.0 (15.1-16.8) years in AMAB individuals. At the time of this report the study was open for inclusion and follow-up measurements were ongoing. Clinical implications: In response to the rising demand for gender-affirming treatment among TGD youth, this ongoing study is fulfilling the need for prospective data on the effects and safety of PS and GAHT, thus providing a foundation for evidence-based healthcare decisions. Strengths and Limitations: This study has a strong multicenter, prospective design that allows for systematic data collection. The use of clinical and self-reported data offers a broad range of outcomes to evaluate. Nevertheless, the burden of additional measurements and questionnaires may lead to withdrawal or lower response rates. Few participants with a non-binary gender identity have been included. Conclusion: With the ENIGI Adolescents study we aim to create a comprehensive dataset that we can use for a wide range of studies to address current controversies and uncertainties and to improve healthcare for TGD adolescents.


  • Open Access

    Time Course of Body Composition Changes in Transgender Adolescents During Puberty Suppression and Sex Hormone Treatment

    by Lidewij Sophia Boogers, Sterre Johanna Petronella Reijtenbagh, Chantal Maria Wiepjes, Adrianus Sarinus Paulus van Trotsenburg, Martin Den Heijer, Sabine Elisabeth Hannema

    Context: Transgender adolescents can undergo puberty suppression (PS) and subsequent gender-affirming hormone therapy (GAHT) but little information is available on the expected rate of physical changes. Objective: To investigate the time course of body composition changes during PS and GAHT. Methods: In this study, retrospective data of 380 trans boys and 168 trans girls treated with PS prior to GAHT from a gender identity clinic were included. Total lean and fat mass Z-scores using birth-assigned sex as reference were determined using dual-energy X-ray absorptiometry. Results: In trans boys, lean mass Z-scores decreased (−0.32, 95% CI −0.41; −0.23) and fat mass Z-scores increased (0.31, 95% CI 0.21; 0.41) in the first year of PS and remained stable thereafter. Lean mass Z-scores increased (0.92, 95% CI 0.81; 1.04) and fat mass Z-scores decreased (−0.43, 95% CI −0.57; −0.29) only during the first year of testosterone,. In trans girls, both lean and fat mass Z-scores gradually changed over 3 years of PS (respectively −1.13, 95% CI −1.29; −0.98 and 1.06, 95% CI 0.90; 1.23). In the first year of GAHT, lean mass Z-scores decreased (−0.19, 95% CI −0.36; −0.03) while fat mass Z-scores remained unchanged after 3 years (−0.02, 95% CI −0.20; 0.16). Conclusion: Compared with peers, trans girls experienced ongoing lean mass decrease and fat mass increase during 3 years of PS while in trans boys smaller changes were observed that stabilized after 1 year. A large increase in lean mass Z-scores occurred only during the first year of testosterone treatment. In trans girls, body composition changed only slightly during GAHT. This information can improve counseling about treatment effects.


  • Open Access

    The dose-dependent effect of estrogen on bone mineral density in trans girls

    by Lidewij Sophia Boogers, Maria Anna Theodora Catharina van der Loos, Chantal Maria Wiepjes, Adrianus Sarinus Paulus van Trotsenburg, Martin Den Heijer, Sabine Elisabeth Hannema

    Objective: Treatment in transgender girls can consist of puberty suppression (PS) with a gonadotropin-releasing hormone agonist (GnRHa) followed by gender-affirming hormonal treatment (GAHT) with estrogen. Bone mineral density (BMD) Z-scores decrease during PS and remain relatively low during GAHT, possibly due to insufficient estradiol dosage. Some adolescents receive high-dose estradiol or ethinyl estradiol (EE) to limit growth allowing comparison of BMD outcomes with different dosages. Design: Retrospective study. Methods: Adolescents treated with GnRHa for ≥1 year prior to GAHT followed by treatment with a regular estradiol dose (gradually increased to 2 mg), 6 mg estradiol or 100-200 µg EE were included to evaluate height-adjusted BMD Z-scores (HAZ scores) on DXA. Results: Eighty-seven adolescents were included. During 2.3 ± 0.7 years PS, lumbar spine HAZ scores decreased by 0.69 [95% confidence interval (CI) −0.82 to −0.56)]. During 2 years HT, lumbar spine HAZ scores hardly increased in the regular group (0.14, 95% CI −0.01 to 0.28, n = 59) vs 0.42 (95% CI 0.13 to 0.72) in the 6 mg group (n = 13), and 0.68 (95% CI 0.20 to 1.15) in the EE group (n = 15). Compared with the regular group, the increase with EE treatment was higher (0.54, 95% CI 0.05 to 1.04). After 2 years HT, HAZ scores approached baseline levels at start of PS in individuals treated with 6 mg or EE (difference in 6 mg group −0.20, 95% CI −0.50 to 0.09; in EE 0.17, 95% CI −0.16 to 0.50) but not in the regular group (−0.64, 95% CI −0.79 to −0.49). Conclusion: Higher estrogen dosage is associated with a greater increase in lumbar spine BMD Z-scores. Increasing dosage up to 2 mg estradiol is insufficient to optimize BMD and approximately 4 mg may be required for adequate serum concentrations.